XML 120 R100.htm IDEA: XBRL DOCUMENT v3.22.4
SHAREHOLDERS' EQUITY (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Feb. 12, 2021
USD ($)
$ / shares
shares
Feb. 09, 2021
USD ($)
$ / shares
shares
May 20, 2020
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 17, 2021
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock offering, shares sold (in shares) | shares 8,750,000 5,650,000        
Stock offering, purchase price (in dollars per share) | $ / shares $ 3.92 $ 2.48        
Stock offering, gross proceeds $ 34,300 $ 14,000        
Stock offering, net proceeds $ 32,200 $ 13,100        
Warrants exercised (in shares) | shares       400,000 1,200,000  
Common shares issued (in shares) | shares       400,000 1,200,000  
Warrants outstanding (in shares)       $ 0    
Issuance of common stock upon exercise of options (in shares) | shares       22,631 72,750  
Proceeds from issuance of common stock       $ 7,020 $ 44,861  
ESPP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Exercise price of awards as percentage of the fair value of common stock (at least)       85.00%    
Shares sold (in shares) | shares         3,929  
Weighted average purchase price of shares sold (in dollars per share) | $ / shares         $ 1.40  
Stock Options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Proceeds from issuance of common stock       $ 0 $ 200  
Zyla Life Sciences            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Merger exchange ratio     2.5      
Zyla Life Sciences | Iroko | Warrant Agreements            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Exercise aggregate ownership percentage maximum threshold (as a percent)     49.00%      
Exercise aggregate ownership percentage term (in months)     18 months      
Zyla Life Sciences | Money market funds | Zyla Life Sciences            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Purchase price, number of shares outstanding, per share (in dollars per share) | $ / shares     $ 0.0016      
At The Market Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Aggregate offering price           $ 25,000
Stock offering, shares sold (in shares) | shares       2,463,637    
Stock offering, purchase price (in dollars per share) | $ / shares       $ 3.02    
Stock offering, gross proceeds       $ 7,400    
Stock offering, net proceeds       $ 7,000